Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice

[1]  A. Brownell,et al.  Positron emission tomography of herpes simplex virus 1 oncolysis. , 2007, Cancer research.

[2]  W. Oyen,et al.  Peritoneal Carcinomatosis of Colorectal Origin: Incidence and Current Treatment Strategies , 2006, Annals of surgery.

[3]  K. Tanabe,et al.  Mouse models of subcutaneous spleen reservoir for multiple portal venous injections to treat liver malignancies. , 2005, Cancer research.

[4]  T. Pawlik,et al.  Oncolysis by viral replication and inhibition of angiogenesis by a replication‐conditional herpes simplex virus that expresses mouse endostatin , 2004, Cancer.

[5]  F. Kwiatkowski,et al.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. van Tinteren,et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Wakimoto,et al.  Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells , 2003, Gene Therapy.

[8]  D. Alberts,et al.  Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Jayne,et al.  Peritoneal carcinomatosis from colorectal cancer , 2002, The British journal of surgery.

[10]  K. Delman,et al.  Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer , 2002, Cancer Gene Therapy.

[11]  T. Pawlik,et al.  Regulation of Herpes Simplex Virus 1 Replication Using Tumor-Associated Promoters , 2002, Annals of surgery.

[12]  T. Pawlik,et al.  Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5 , 2002 .

[13]  Takuma Sasaki,et al.  Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. , 2001, Hepato-gastroenterology.

[14]  T. Pawlik,et al.  Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. , 2001, Cancer research.

[15]  H. Chung,et al.  Indications for Early Postoperative Intraperitoneal Chemotherapy of Advanced Gastric Cancer: Results of a Prospective Randomized Trial , 2001, World Journal of Surgery.

[16]  K. Delman,et al.  Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. , 2000, Human gene therapy.

[17]  Sam S. Yoon,et al.  An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  G. Coukos,et al.  Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy , 2000, Cancer Gene Therapy.

[19]  S. Nomoto,et al.  Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer , 1999, Journal of surgical oncology.

[20]  D. Louis,et al.  Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses , 1999, Nature Medicine.

[21]  D. Curiel,et al.  Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector , 1999, Gene Therapy.

[22]  K. Hatakeyama,et al.  Blood Flow and Leukocyte Adhesiveness Are Reduced in the Microcirculation of a Peritoneal Disseminated Colon Carcinoma , 1998, Annals of Biomedical Engineering.

[23]  E. Chiocca,et al.  Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. , 1998, Annals of surgery.

[24]  E. Chiocca,et al.  Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. , 1996, Annals of surgery.

[25]  S. Weller,et al.  A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. , 1989, Virology.

[26]  K. Westbrook,et al.  Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors , 1989, Cancer.

[27]  S. Weller,et al.  Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. , 1988, Virology.

[28]  S. Weller,et al.  Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant , 1988, Journal of virology.

[29]  N. Geller,et al.  Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Teicher,et al.  Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. , 1981, Cancer research.

[31]  M. Luczak,et al.  In vitro andin vivo inhibition of virus multiplication by microwave hyperthermia , 2005, Archives of Virology.

[32]  T. Pawlik,et al.  Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. , 2002, The Journal of clinical investigation.

[33]  K. Tanabe,et al.  Viral oncolysis. , 2002, The oncologist.

[34]  P. Sugarbaker.  Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. , 1996, Cancer treatment and research.

[35]  M. Luczak,et al.  Influence of hyperthermia on experimental viral infections in vitro. , 1990, Advances in experimental medicine and biology.

[36]  W. Cunliffe,et al.  Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. , 1989, Seminars in oncology.

[37]  E. De Clercq,et al.  In vitro and in vivo inhibition of virus multiplicaton by microwave hyperthemia. , 1977, Archives of virology.